90-60-8

Basic information

• Product Name: 3,5-DICHLOROSALICYLALDEHYDE
• Synonyms: Benzaldehyde,3,5-dichloro-2-hydroxy-;Salicylaldehyde, 3,5-dichloro-;Salicylaldehyde,3,5-dichloro-;AKOS B029257;3,5-DICHLORO SALICYLAL;3,5-DICHLOROSALICYLALDEHYDE;3,5-DICHLORO-2-HYDROXYBENZALDEHYDE;LABOTEST-BB LT00089371
• CAS NO: 90-60-8
• Molecular Formula: C₇H₄Cl₂O₂
• Molecular Weight: 191.01
• EINECS: 202-005-5
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Benzaldehyde;Aldehydes;C7;Carbonyl Compounds
• Mol File: 90-60-8.mol

Chemical Properties

• Melting Point: 95-97 °C(lit.)
• Boiling Point: 273.68°C (rough estimate)
• Flash Point: 96.9 °C
• Appearance: Pale yellow/Crystalline Powder
• Density: 1.4410 (rough estimate)
• Vapor Pressure: 0.0304mmHg at 25°C
• Refractive Index: 1.4590 (estimate)
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: ethanol: soluble5%, clear, faintly yellow to greenish-yellow
• PKA: 6.27±0.23(Predicted)
• Water Solubility: Insoluble in water. Solubility in methanol is almost transparent.
• Sensitive: Air Sensitive
• BRN: 973391
• CAS DataBase Reference: 3,5-DICHLOROSALICYLALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DICHLOROSALICYLALDEHYDE(90-60-8)
• EPA Substance Registry System: 3,5-DICHLOROSALICYLALDEHYDE(90-60-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 90-60-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3,5-Dichlorosalicylaldehyde is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be easily modified and incorporated into a variety of drug molecules, making it a valuable component in the development of new medications.
Used in Organic Chemistry:
3,5-Dichlorosalicylaldehyde is used as a versatile building block in organic chemistry for the preparation of various organic compounds. Its reactivity and ability to form a wide range of chemical bonds make it a useful starting material for the synthesis of complex organic molecules.
Used in the Preparation of Schiff Base Ligands:
3,5-Dichlorosalicylaldehyde is used as a starting material in the preparation of Schiff base ligands. Schiff bases are a class of compounds formed by the condensation of a primary amine with an aldehyde or ketone. These ligands are widely used in coordination chemistry, as they can form stable complexes with metal ions, making them useful in various applications, such as catalysis and the development of new materials.
Used in the Preparation of (RS)-3,5-Dichloro-2-[[(1-Phenylethyl)imino]methyl]Phenol:
3,5-Dichlorosalicylaldehyde is also used in the preparation of (RS)-3,5-dichloro-2-[[(1-phenylethyl)imino]methyl]phenol, a specific organic compound with potential applications in various fields. The synthesis of 3,5-DICHLOROSALICYLALDEHYDE demonstrates the versatility of 3,5-dichlorosalicylaldehyde as a starting material for the preparation of a wide range of organic compounds.

InChI:InChI=1/C7H4Cl2O2/c8-5-1-4(3-10)7(11)6(9)2-5/h1-3,11H

Upstream product

• 64-17-5 ethanol 
• 100-97-0 hexamethylenetetramine 
• 120-83-2 2,4-dichlorophenol 
• 6641-02-7 3,5-dichloro-2-hydroxybenzyl alcohol 
• 127-68-4 sodium 3-nitrobenzenesulfonate 
• 6333-33-1 2,4-dichloro-6-(chloromethyl)phenol 
• 855156-83-1 bis-(3,5-dichloro-2-hydroxy-benzyl)-ether 
• 90-02-8 salicylaldehyde 
• 67-66-3 chloroform 
• 7782-50-5 chlorine 
• 64-19-7 acetic acid 
• 13460-50-9 metaboric acid 
• 56-81-5 glycerol 
• 75-75-2 methanesulfonic acid 

Downstream Products

• 96460-25-2 1-<3,5-dichlorosalicylidene>-2-hydrazine 
• 107919-17-5 N-(3,5-dichloro-2-hydroxy-benzylidene)-sulfanilic acid-[2]pyridylamide 
• 2199-91-9 3-acetyl-6,8-dichloro-2H-1-benzopyran-2-one 
• 93203-72-6 3,5,4'-trichloro-2-hydroxy-trans-chalcone 
• 14817-67-5 4-(3,5-dichloro-2-hydroxy-benzylidenamino)-2-hydroxy-benzoic acid 
• 77463-79-7 6,6'-((1E,1'E)-(ethane-1,2-diylbis(azanylylidene))bis(methanylylidene))bis(2,4-dichlorophenol) 
• 52828-99-6 2-(1H-benzoimidazol-2-yl)-4,6-dichloro-phenol 
• 79319-60-1 (E)-2,4-dichloro-6-(((2-hydroxyphenyl)imino)methyl)phenol 
• 14897-93-9 4-(3,5-dichloro-2-hydroxy-benzylidenamino)-benzoic acid ethyl ester 
• 99515-71-6 2,4-dichloro-6-(4,6-dichloro-1H-benzimidazol-2-yl)-phenol 

Relevant articles and documents

Phosphine-catalyzed sequential (2+3)/(2+4) annulation of γ-vinyl allenoates: Access to the synthesis of chromeno[4,3-: B] pyrroles

A phosphine-catalyzed cascade (2+3)/(2+4) cyclization reaction of γ-vinyl allenoates with aldimine esters has been developed to provide a series of chromeno[4,3-b]pyrrole derivatives that contain three contiguous stereogenic centers. The method gives a good yield, excellent chemoselectivity and diastereoselectivity under mild conditions.

Cytotoxicity of new pyridazin-3(2H)-one derivatives orchestrating oxidative stress in human triple-negative breast cancer (MDA-MB-468)

Triple-negative breast cancer (TNBC) is a complex and aggressive subtype of breast cancer characterized by high morbidity and mortality. In the absence of targeted therapy, only chemotherapy is available in this case of cancer. The current study investigated the antitumor effect of new pyridazin-3(2H)-one derivatives on the human TNBC cell line, MD-MB-468. The in vitro cytotoxic activities were investigated using the tetrazolium-based MTT assay. Lipid peroxidation, H2O2 content, and the specific activities of antioxidant enzymes were also determined. Two molecules, 6f and 7h, were found to be selectively highly active against tumor cells with IC50 values of 3.12 and 4.9 μM, respectively. Furthermore, cells exposed to 6f showed a significant increase in H2O2 and lipid peroxidation levels, accompanied by a decrease in the enzyme activities of glutathione reductase (GR) and thioredoxin reductase (TrxR). The cytotoxicity of the compound 6f may improve the therapeutic efficacy of the current treatment for TNBC via the inhibition of GR and TrxR activities.

Design and synthesis of novel Vitamin D-coumarin hybrids using microwave irradiation

A series of novel vitamin D-coumarin hybrids were synthesised by esterification of the corresponding coumarin-3-carboxylic acids and vitamin D or vitamin D CD-ring alcohol in CH2Cl2 under microwave irradiation. They were obtained in higher yields (from 64-81% up to 79-87%) and shorter reaction time (from 3 h down to 15 min), compared with earlier conventional methodologies. The structures of all the target compounds were confirmed by 1H NMR, 13C NMR and HRMS. This provides an attractive and alternative method for the preparation of high-value vitamin D-coumarin hybrids.

Synthesis characterization and cytotoxicity studies of platinum(II) complexes with reduced amino pyridine schiff base and its derivatives as ligands

A series of reduced amino pyridine Schiff base platinum(II) complexes were prepared as potential anticancer drugs, and characterized by NMR, IR spectroscopy, elemental analysis, and molar conductivity. UV and CD results showed the binding mode between these compounds and salmon sperm DNA may be intercalation. The cytotoxicity of these complexes was validated against A549, Hela, and MCF-7 cell lines by MTT assay. Some complexes exhibited better cytotoxic activity than cisplatin against Hela and MCF-7 cell lines.

NO-RELEASING NITROOXY-CHROMENE CONJUGATES

The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1).

NO-RELEASING NITROOXY-CHROMENE CONJUGATES

The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1 ) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1).

NO-RELEASING NONOATE(OXYGEN-BOUND)CHROMENE CONJUGATES

The present invention provides NO-releasing NONOate(oxygen bound)chromene conjugates, having the structure of Formula (I): wherein Z, R1, R2, R3, R4, R5, R6, and R7 are as defined in the detailed description; pharmaceutical compositions comprising at least one compound of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis, or acne, using a compound of Formula (I).

NO-RELEASING GUANIDINE-CHROMENE CONJUGATES

The present disclosure provides NO-releasing guanidine-chromene conjugates, having the structure of Formula (I): wherein R1, R2, R3, R4, R10, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis, acne, or a disease mediated by arginine deficiency using a compound of Formula (I).

Cu-Mn spinel oxide catalyzed regioselective halogenation of phenols and N-heteroarenes

A novel simple, mild chemo- and regioselective method has been developed for the halogenation of phenols using Cu-Mn spinel oxide as a catalyst and N-halosuccinimide as halogenating agent. In the presence of Cu-Mn spinel oxide B, both electron-withdrawing and electron-donating groups bearing phenols gave monohalogenated products in good to excellent yields with highest para-selectivity. The para-substituted phenol gave monohalogenated product with good yield and ortho-selectivity. N-Heteroarenes such as indoles and imidazoles also gave monohalogenated products with high selectivity. Unlike the copper-catalyzed halogenation, the present method works well with electron-withdrawing group bearing phenols and gives comparatively better yields and selectivity. The Cu-Mn spinel catalyst is robust and reused three times under optimized conditions without any loss in catalytic activity. Nonphenolics did not undergo this transformation.